Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1986 2
1987 15
1988 27
1989 37
1990 62
1991 43
1992 59
1993 98
1994 66
1995 63
1996 70
1997 78
1998 79
1999 63
2000 69
2001 110
2002 110
2003 123
2004 108
2005 81
2006 94
2007 136
2008 118
2009 125
2010 119
2011 127
2012 122
2013 127
2014 98
2015 104
2016 116
2017 91
2018 102
2019 80
2020 89
2021 71
2022 68
2023 80
2024 59

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,114 results

Results by year

Filters applied: . Clear all
Page 1
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. Hochhaus A, et al. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3. Leukemia. 2020. PMID: 32127639 Free PMC article. Review.
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. ...A change of treatment is recommended when intolerance cannot be ameliorated o …
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with …
Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.
Minciacchi VR, Kumar R, Krause DS. Minciacchi VR, et al. Cells. 2021 Jan 10;10(1):117. doi: 10.3390/cells10010117. Cells. 2021. PMID: 33435150 Free PMC article. Review.
Chronic myeloid leukemia (CML) has been a "model disease" with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after targe …
Chronic myeloid leukemia (CML) has been a "model disease" with a long history. Beginning with the first discovery of leukem …
Response and Resistance to BCR-ABL1-Targeted Therapies.
Braun TP, Eide CA, Druker BJ. Braun TP, et al. Cancer Cell. 2020 Apr 13;37(4):530-542. doi: 10.1016/j.ccell.2020.03.006. Cancer Cell. 2020. PMID: 32289275 Free PMC article. Review.
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. ...Some patients develop TKI resistance without known resistanc …
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a …
Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Senapati J, et al. Blood Cancer J. 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9. Blood Cancer J. 2023. PMID: 37088793 Free PMC article. Review.
With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line therapy of CML. In the frontline therapy of CML in the chronic phase (CML-CP), ima …
With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR …
Chronic Myeloid Leukemia: Beyond BCR-ABL1.
Zhou T, Medeiros LJ, Hu S. Zhou T, et al. Curr Hematol Malig Rep. 2018 Dec;13(6):435-445. doi: 10.1007/s11899-018-0474-6. Curr Hematol Malig Rep. 2018. PMID: 30370478 Review.
PURPOSE OF REVIEW: In this review, we emphasize up-to-date practical cytogenetic and molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on tyrosine kinase inhibitor (TKI) resistance and treatment response monitoring of CML. ...Over t …
PURPOSE OF REVIEW: In this review, we emphasize up-to-date practical cytogenetic and molecular aspects of chronic myeloid leukemia …
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG, Deininger MW. Osman AEG, et al. Blood Rev. 2021 Sep;49:100825. doi: 10.1016/j.blre.2021.100825. Epub 2021 Mar 16. Blood Rev. 2021. PMID: 33773846 Free PMC article. Review.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal translocation [t(9;22)(q34;q11.2)] that leads to the fusion of ABL1 gene sequences (9q34) downstream of BCR gene sequences (22q11) and is cytogenetically visible as …
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal translocation [t(9;22)(q34;q11.2)] that …
Chronic myeloid leukaemia.
Cortes J, Pavlovsky C, Saußele S. Cortes J, et al. Lancet. 2021 Nov 20;398(10314):1914-1926. doi: 10.1016/S0140-6736(21)01204-6. Epub 2021 Aug 20. Lancet. 2021. PMID: 34425075 Review.
Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy. ...If these …
Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate ac …
Olverembatinib: First Approval.
Dhillon S. Dhillon S. Drugs. 2022 Mar;82(4):469-475. doi: 10.1007/s40265-022-01680-9. Drugs. 2022. PMID: 35195876 Review.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, …
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma f …
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, Soverini S. Cross NCP, et al. Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4. Leukemia. 2023. PMID: 37794101 Free PMC article. Review.
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of possible reasons for resista …
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagno …
Chronic Myeloid Leukemia in Children and Adolescents.
Gotesman M, Raheel S, Panosyan EH. Gotesman M, et al. Adv Pediatr. 2023 Aug;70(1):145-155. doi: 10.1016/j.yapd.2023.04.002. Epub 2023 May 12. Adv Pediatr. 2023. PMID: 37422292 Review.
Acute leukemia is the most common malignancy in childhood, while chronic myeloid leukemia is rare, accounting for only 2% to 3% of all leukemia in childhood and 9% in adolescents, with an annual incidence of 1 and 2.2 cases per million in the two group …
Acute leukemia is the most common malignancy in childhood, while chronic myeloid leukemia is rare, accounting for only …
3,114 results